Also published in MarketWatch:
Questions Every Board Director Needs to Ask about Technology
x hide permanently

Gilead Reaches $21 Billion Deal for Immunomedics


Gilead Sciences Inc. will pay $21 billion to buy biotech Immunomedics Inc. and its prized breast-cancer drug, the company said Sunday, a sign of the value of the cancer-drugs business. Immunomedics has a market value of roughly $10 billion following a recent surge in its stock, meaning that Gilead is paying up to secure ownership of the company. Gilead agreed to pay $88 a share in cash for Immunomedics, whose shares closed at $42.25 Friday. That represents a 108% premium...

Mentions: acquisition stake Gilead Sciences